ALPIB
ALPINE BANKS OF COLORADO$48.07 −0.07 (−0.15%)
Oct 26 4:00 PM ET · prev $48.14
Next earnings
Oct 28
in 2 days
1 year
+40.1%
from $34.30 · Oct 27
30 days
−1.9%
from $48.99
52-week range
$34.30–50.87
−5% from high · low Oct 27
Avg volume 20D
550
Sep 29 spike 4.5K
Short interest
10
0.0%
Days to cover
1.0
at average volume
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E Apr 2 Trial readout: T-90d Trial Readout: povetacicept (Phase 2)
- E Apr 6 Trial readout: T-90d Trial Readout: povetacicept (Phase 2)
- X Jul 31 Short interest jumps 87.3% to 294
- X Aug 14 Short interest falls 50.0% to 147
- X Aug 31 Short interest falls 93.2% to 10
Signal stack
Where each data set points today.
- Short sellersSTEADY
Short interest 0.0% to 10 shares. 1.0 days to cover.
- TrendDOWNTREND
2% below its 50-day average.
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Jul 29, 2026 Earnings calendar
ALPIB Q2 2026 Earnings Scheduled — 2026-07-29
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Recent
Jul 29, 2026
Earnings date
ALPIB Q2 2026 Earnings Scheduled — 2026-07-29
Apr 28, 2026
Earnings date
ALPIB Q1 2026 Earnings Scheduled — 2026-04-28
Apr 5, 2026
Trial readout
T-90d Trial Readout: povetacicept (Phase 2)
Trial: An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias Sponsor: Alpine Immune Sciences, Inc. Phase: Phase 2 | Status…
Apr 1, 2026
Trial readout
T-90d Trial Readout: povetacicept (Phase 2)
Trial: An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias Sponsor: Alpine Immune Sciences, Inc. Phase: Phase 2 | Status…
Earnings setup
EstimatesOct 28
reports in 2 days
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Sep 30, 202610
shares short
0.0%
vs prior settlement
1.0
days to cover